Literature DB >> 18417314

Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.

D Collins1, P F Ridgway, D C Winter, D Fennelly, D Evoy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18417314     DOI： 10.1016/j.ejso.2008.02.013

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN： 0748-7983            Impact factor:   4.424


× No keyword cloud information.
  5 in total

1.  Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.

Authors:  Motohiro Tamiya; Hidekazu Suzuki; Takayuki Shiroyama; Ayako Tanaka; Naoko Morishita; Norio Okamoto; Kenichi Sakai; Hironori Shigeoka; Kunimitsu Kawahara; Tomonori Hirashima
Journal:  Invest New Drugs       Date:  2018-03-14       Impact factor: 3.850

2.  Electrical field stimulation promotes anastomotic healing in poorly perfused rat colon.

Authors:  Rory Kennelly; John B Conneely; David J Bouchier-Hayes; Desmond C Winter
Journal:  Int J Colorectal Dis       Date:  2010-09-01       Impact factor: 2.571

Review 3.  Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review.

Authors:  T O'Hare; R McDermott; R Hannon
Journal:  Ir J Med Sci       Date:  2017-08-29       Impact factor: 1.568

Review 4.  Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.

Authors:  Efstathios T Pavlidis; Theodoros E Pavlidis
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

5.  Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports.

Authors:  Ching-Chun Li; Hsiang-Lin Tsai; Ching-Wen Huang; Yung-Sung Yeh; Tzu-Hsueh Tsai; Jaw-Yuan Wang
Journal:  Mol Clin Oncol       Date:  2018-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.